Contec Medical Systems Co. Ltd. Class A

Contec Medical Systems Co. Ltd. Class A

SSZSE:300869
9.25
CNY
-0.24
(-2.53%)
-0.23EPS
4.56BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.22
2.5
3.04
1.28
1.08
0.99
1.05
3.75
2.27
1.78
1.85
1.17
1.15
1.19
Basic EPS, GAAP
0.56
0.54
0.71
0.3
0.21
0.17
0.2
1.64
0.88
0.49
0.41
-0.19
-0.06
-0.23
Free Cash Flow per Basic Share
0.38
0.21
0.4
0.34
0.31
0.05
0.12
1.36
-0.25
0.06
0.37
0.02
-0.07
- -
Dividend per Share
0.11
0.07
0.26
0.36
- -
- -
- -
- -
0.26
0.31
0.17
0.31
0.28
0.04
Book Value per Share
1.78
2.23
3.02
3.46
1.24
1.41
1.62
3.9
4.53
4.8
5.09
4.62
4.31
4.17
Tangible Book Value per Share
1.69
2.12
2.87
3.32
1.21
1.36
1.57
3.87
4.45
4.66
4.95
4.49
4.19
4.05
Basic Weighted Avg Shares
96
101
102
345
367
365
369
374
400
400
404
410
407
402
Sales/Revenue/Turnover
214
252
309
442
398
363
387
1,401
909
712
747
480
468
478
Operating Margin (%)
26.22
20.55
19.94
21.43
23.87
17.63
18.26
50.12
32.04
17.21
24.16
0.23
-2.99
-7.48
Depreciation Expense
7
12
13
15
15
15
14
15
18
21
28
28
28
- -
Net Income, GAAP
54
54
72
103
77
62
74
613
352
196
166
-78
-24
-91
Effective Tax Rate (%)
11.63
9.67
12.01
13.64
12.49
10.56
9.92
14.27
13.64
10.57
10.94
- -
- -
- -
Profit Margin (%)
25.18
21.6
23.38
23.41
19.37
17.1
19.05
43.78
38.78
27.55
22.19
-16.24
-5.22
-19.07
Working Capital
59
105
184
247
337
402
304
752
396
1,446
2,022
1,786
2,064
2,028
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
3
671
698
725
751
764
Total Equity
183
229
310
371
447
509
583
1,569
1,820
1,928
2,045
1,857
1,733
1,674
Return on Invested Capital (%)
- -
21.22
22.34
23.06
17.77
13.56
13.54
48.42
15.28
6.33
5
- -
- -
- -
Return on Capital (%)
- -
26.85
26.79
30.41
18.85
12.98
13.29
50.47
15.91
6.96
6.24
- -
- -
- -
Return on Common Equity (%)
- -
26.44
26.79
30.41
18.85
12.98
13.51
57.01
20.79
10.47
8.34
-3.99
-1.36
-5.28

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
226
96
46
LT Borrowings
758
766
763
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
402
402
402
Market Capitalization
5,332
4,155
4,560

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,369
2,217
2,155
Cash, Cash Equivalents & STI
1,804
1,877
1,815
Accounts Receivable, Net
36
42
47
Inventories
237
210
224
Total Current Liabilities
304
182
127
Payables & Accruals
- -
- -
- -
ST Debt
226
96
46
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.99%
2.43%
-6.69%
Free Cash Flow
112.59%
-40.99%
-444.97%
Net Income, GAAP
43.07%
-63.61%
-68.65%
Sales/Revenue/Turnover
20.29%
-18.02%
-2.46%
Total Cash Common Dividend
- -
1,091.32%
-12.22%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
99
113
122
146
480
2025
112
106
- -
124
468
2026
100
126
128
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
- -
-0.22
-0.19
2025
0.04
- -
- -
-0.08
-0.06
2026
-0.02
-0.1
-0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.3
0.01
- -
0.31
2025
- -
0.25
- -
- -
0.28
2026
- -
- -
0.03
- -
- -

Company Description

CEO
Zhi Shan Yang
Full Time Employees
1,712
Sector
Health technology
Industry
Medical specialties
Address
No.112 Qinhuang West Street Qinhuangdao HE China 066004
IPO Date
Aug 24, 2020
Business
Contec Medical Systems Co., Ltd. (300869.SZ) researches, develops, manufactures, and sells medical diagnosis and monitoring equipment. The company offers a broad portfolio of products across more than 20 categories, including pulse oximeters; sphygmomanometers and blood pressure monitors; electrocardiograph systems such as resting ECG, dynamic ECG, and stress ECG; patient monitors and central monitoring systems; ultrasound equipment encompassing B ultrasound, color Doppler ultrasound, and pocket fetal Doppler; endoscopes and camera systems; in vitro diagnostics like semi-automatic and automatic biochemistry analyzers, hematology analyzers, urine analyzers, and POCT devices; EEG and EMG systems; infusion and syringe pumps; respiratory aids including oxygen concentrators; telemedicine solutions; veterinary equipment; stethoscopes; thermometers; sleep and snoring aids; massagers; simulators; and related accessories. These products serve medical institutions, clinics, household users, and veterinary applications, with sales through distributors in over 130 countries and regions worldwide. Founded in 1996 and headquartered in Qinhuangdao, Hebei Province, China, the company operates as a high-tech enterprise with a production base spanning over 67,450 square meters and more than 1,000 employees. It maintains subsidiaries including Contec Medical Systems USA Inc. in Chicago (established 2012), Contec Medical Systems India Pvt Ltd. in New Delhi (2019), and Contec Medical Systems Germany GmbH in Dusseldorf (2019), supporting its international expansion. [aboutus page] Products hold certifications such as CE, FDA, and approvals from Canada, Japan, and Brazil. In recent years, Contec listed on the Shenzhen Stock Exchange in August 2020 (stock code: 300869), marking a key milestone for capital access and growth. [aboutus page] The company initiated a major production base expansion project in February 2021, covering 38,318.82 square meters with a total investment of 219.2725 million yuan to enhance manufacturing capacity, industrial optimization, and employment. [newsinfo/496094.html] It continues pursuing market expansions into Southeast Asia and Europe with an expected 15% CAGR, alongside strategic acquisitions enabled by cash reserves and a recent 500 million yuan debt issuance rated BBB to fund R&D and production upgrades.